Article information
Abstract
Purpose
This study was planned to evaluate the prevalence of HPV (excepting type 16) and HPV 16 by real-time PCR in colposcopy patients and to interprete the results with age, age of first sexual intercourse (FSI), parity and Pap smear results.
MethodsOne hundred and two colposcopy patients (50 and 52 of the patients were classified as colposcopy positive and negative, respectively) applying to Gynecology clinic were included. HPV (excepting type 16) and HPV 16 were detected by real-time PCR using the L1 region. Real-time nested amplifications of MY09/11 products were done by GP5+/GP6+ primers and Cyanine-5 labeled HPV and HPV 16 DNA specific probe after HPV DNA extraction by phenol chloroform isoamylalcohol.
ResultsHPV (excepting type 16) and HPV 16 were positive in 12% and 18% of the colposcopy positive patients respectively. HPV (excepting type 16) and HPV 16 were positive in 5.7% and 3.8% of the colposcopy negative patients, respectively.
ConclusionThere was a statistically significant difference between colposcopy positive and colposcopy negative patients comparing HPV 16 with total HPV positivity (p=0.021 for type 16 and p=0.010 for total HPV) but there was not a statistically significant difference between colposcopy positive and colposcopy negative patients when we compared HPV (excepting type 16) positivity (p=0.314). In conclusion, HPV detection and typing may be helpful for cervical cancer screening and prevention.
Keywords:
HPV type 16
real-time PCR
colposcopy
Full text is only aviable in PDF
References
[1.]
B.J. Monk, T.J. Herzog.
The new era of cervical cancer prevention: HPV vaccination.
Gynecol Oncol, 109 (2008), pp. S1-S3
[2.]
J.L. Benedet.
Progress in gynecologic cancer detection and treatment.
International Journal of Gynecology and Obstetrics, 70 (2000), pp. 135-147
[3.]
A. Spinillo, M. Debiaggi, F. Zara, et al.
Human Immunodeficiency Virus Type 1- Related Nucleic Acids and Papillomavirus DNA in Cervicovaginal Secretions of Immunodeficiency Virus- Infected Women.
Obstetrics and Gynecology, 97 (2001), pp. 999-1004
[4.]
E. Matos, D. Loria, G.M. Amestoy, et al.
Prevalance of Human Papillomavirus Infection Among Women in Concordia, Argentina: A Population-Based Study.
Sexually Transmitted Diseases, 27 (2003), pp. 593-599
[5.]
M. Moberg, I. Gustavsson, U. Gyllensten.
Real-Time PCR-Based System for Simultaneous Quantification of Human Papillomavirus Types Associated with High Risk of Cervical Cancer.
Journal of Clinical Microbiology, 41 (2003), pp. 3221-3228
[6.]
E.L. Franco, E. Duarte-Franco, A. Ferenczy.
Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.
CMAJ, 164 (2001), pp. 1017-1025
[7.]
C. Perrons, B. Kleter, R. Jelley, et al.
Detection and Genotyping of Human Papillomavirus DNA by SPF10 and MY09/11 Primers in Cervical Cells Taken From Women Attending a Colposcopy Clinic.
Journal of Medical Virology, 67 (2002), pp. 246-252
[8.]
J. Severson, T. Evans, P. Lee, et al.
Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy.
Journal of Cutaneous Medicine and Surgery, 5 (2001), pp. 43-60
[9.]
E.J Mayeaux.
Reducing the economic burden of HPV-related diseases.
J Am Osteopath Assoc, 108 (2008), pp. 52-57
[10.]
S. Tuncer, S. Ustacelebi.
Detection of Human Papillomavirus Type 16 and 18 by polymerase chain reaction in cervical biopsy samples.
Flora, 1 (1996), pp. 40-44
[11.]
M.A. Onan, C. Taskiran, G. Bozdayi, et al.
Assessment of human papilloma viral load of archival cervical intraepithelial neoplasia by real-time polymerase chain reaction in a Turkish population.
Eur J Gynaecol Oncol, 26 (2005), pp. 632-635
[12.]
S. Ozturk, I. Kaleli, B. Kaleli, F. Bir.
Investigation of human papillomavirus DNA in cervical specimens by hybrid capture assay.
Mikrobiyol Bul, 38 (2004), pp. 223-232
[13.]
L.H. Oliveira, M.L. Rosa, C.R. Pereira, et al.
Human papillomavirus status and cervical abnormalities in women from public and private health care in Rio de Janeiro State, Brazil.
Rev Inst Med Trop São Paulo, 48 (2006), pp. 279-285
[14.]
E.F. Dunne, E.R. Unger, M. Sternberg, et al.
Prevalence of HPV infection among females in the United States.
JAMA, 297 (2007), pp. 813-819
[15.]
C. Ferreccio, A. Corvalan, P. Margozzini, et al.
Baseline assessment of prevalence and geographical distribution of HPV types in Chile using self-collected vaginal samples.
BMC Public Health, 8 (2008), pp. 78
[16.]
V. Ko, S. Nanji, R.H. Tambouret, D.C. Wilbur.
Testing for HPV as an objective measure for quality assurance in gynecologic cytology: positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio.
Cancer, 111 (2007), pp. 67-73
[17.]
J.W. Sellors, J.B. Mahony, J. Kaczorowski, et al.
Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada.
CMAJ, 163 (2000), pp. 503-508
[18.]
J.A. Kahn, S.L. Rosenthal, P.A. Succop, et al.
Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection.
Pediatrics, 109 (2002), pp. E5
[19.]
Y.N. Flores, D.M. Bishai, K.V. Shah, et al.
Risk factors for cervical cancer among HPV positive women in Mexico.
Salud Publica Mex, 50 (2008), pp. 49-58
[20.]
P.E. Castle, S. Wacholder, A.T. Lorincz, et al.
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.
J Natl Cancer Inst, 94 (2002), pp. 1406-1414
[21.]
S. Vaccarella, R. Herrero, M. Dai, et al.
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys.
Cancer Epidemiol Biomarkers Prev, 15 (2006), pp. 2148-2153
[22.]
T.S. Shields, L.A. Brinton, R.D. Burk, et al.
A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus.
Cancer Epidemiol Biomarkers Prev, 13 (2004), pp. 1574-1582
[23.]
X. Castellsagué, M. Díaz, S. de Sanjosé, et al.
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
J Natl Cancer Inst, 98 (2006), pp. 303-315
[24.]
M.H. Mayrand, E. Duarte-Franco, I. Rodrigues, et al.
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
N Engl J Med, 357 (2007), pp. 1579-1588
[25.]
P. Naucler, W. Ryd, S. Törnberg, et al.
Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
N Engl J Med., 357 (2007), pp. 1589-1597
[26.]
J. Cuzick.
Role of HPV testing in clinical practice.
Virus Research., 89 (2002), pp. 263-269
[27.]
M. Grce, K. Husnjak, J. Bozikov, et al.
Evaluation of Genital Human Papillomavirus Infections by Polymerase Chain Reaction among Croatian Women.
Anticancer Research., 21 (2001), pp. 579-584
[28.]
K.H. Fife, H.M. Cramer, J.M. Schroeder, D.R. Brown.
Detection of Multiple Human Papillomavirus Types in the Lower Genital Tract Correlates With Cervical Dysplasia.
Journal of Medical Virology., 64 (2001), pp. 550-559
[29.]
Y.Y. Yang, L.W. Koh, C.H. Tsai, et al.
Correlation of viral factors with cervical cancer in Taiwan.
J Microbiol Immunol Infect., 37 (2004), pp. 282-287
[30.]
N.A. Antonishyn, G.B. Horsman, R.A. Kelln, et al.
The impact of the distribution of human papillomavirus types and associated high-risk lesions in a colposcopy population for monitoring vaccine efficacy.
Arch Pathol Lab Med., 132 (2008), pp. 54-60
[31.]
K.V. Shah, L. Solomon, R. Daniel, et al.
Comparison of PCR and Hybrid Capture Methods for Detection of Human Papillomavirus in Injection Drug- Using Women at High Risk of Human Immunodeficiency Virus Infection.
Journal of Clinical Microbiology, 35 (1997), pp. 517-519
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
